Usability and Tolerability of the Norditropin NordiFlex® Injection Device in Children Never Previously Treated With Growth Hormone

• Status: Completed
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is conducted in Europe. The purpose of this study is to assess the impact on daily life for children new to using a growth hormone injection device.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Hormones

Criteria

Inclusion Criteria:

• Growth hormone (GH) treatment naïve subjects for whom it has been decided to initiate GH treatment prior to enrollment into the study

• Subjects who receive Norditropin NordiFlex® according to the SPC

Exclusion Criteria:

• Known or suspected allergy to study product(s) or related products

• Child and/or parent unable to give consent or fill out the questionnaires

• The receipt of any investigational medicinal product within 3 months prior to this study

• Suffer from a life-threatening disease